Compare
Haemonetics Corp vs Penumbra Inc vs Merit Medical Systems Inc vs Integra Lifesciences Holdings Corp
| Latest fiscal year | Haemonetics Corp HAE | Penumbra Inc PEN | Merit Medical Systems Inc MMSI | Integra Lifesciences Holdings Corp IART |
|---|---|---|---|---|
| Year ended | 2026-03-28 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.33B | $1.40B | $1.52B | $1.64B |
| Revenue growth (YoY) | -2.0% | +17.5% | +11.8% | +1.5% |
| Gross margin | 59.0% | 67.1% | 48.7% | 50.9% (computed) |
| Operating margin | 11.7% | 13.5% | 12.2% | -30.2% |
| Net margin | 7.3% | 12.7% | 8.5% | -31.6% |
| Net income | $97.31M | $177.69M | $128.49M | -$516.47M |
| EPS (Diluted) | $2.05 | $4.52 | $2.13 | -$6.74 |
| Operating cash flow | $293.22M | $238.66M | $297.37M | $50.38M |
| Free cash flow | $260.44M | $174.93M | $215.66M | -$31.05M |
| Cash & equivalents | $245.44M | $186.90M | $446.40M | $235.05M |
| Total assets | $2.40B | $1.83B | $2.69B | $3.60B |
| Total liabilities | n/a | $398.92M | $1.10B | $2.56B |
| Shareholders' equity | $796.32M | $1.43B | $1.58B | $1.04B |
| Return on year-end equity | 12.2% | 12.4% | 8.1% | -49.5% |
| Shares outstanding | 45.25M | 39.23M | 59.42M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Haemonetics Corp | Penumbra Inc | Merit Medical Systems Inc | Integra Lifesciences Holdings Corp |
|---|---|---|---|---|
| Latest | $1.33B Ended 2026-03-28 | $1.40B Ended 2025-12-31 | $1.52B Ended 2025-12-31 | $1.64B Ended 2025-12-31 |
| 1 year earlier | $1.36B Ended 2025-03-29 | $1.19B Ended 2024-12-31 | $1.36B Ended 2024-12-31 | $1.61B Ended 2024-12-31 |
| 2 years earlier | $1.31B Ended 2024-03-30 | $1.06B Ended 2023-12-31 | $1.26B Ended 2023-12-31 | $1.54B Ended 2023-12-31 |
| 3 years earlier | $1.17B Ended 2023-04-01 | $847.13M Ended 2022-12-31 | $1.15B Ended 2022-12-31 | $1.56B Ended 2022-12-31 |
| 4 years earlier | $993.20M Ended 2022-04-02 | $747.59M Ended 2021-12-31 | $1.07B Ended 2021-12-31 | $1.54B Ended 2021-12-31 |